References:
1. Rocha e Silva M, Beraldo WT, Rosenfeld G ”Bradykinin, a hypotensive
and smooth muscle stimulating factor released from plasma globulin by
snake venoms and by trypsin”. American Journal of Physiology. 156 (2):
261–73.
2. Almeida, Teresa & Rojo, Javier & Nieto, Pedro & Pinto, Francisco
& Hernandez Ferrer, Mariano & Martín et al. Tachykinins and Tachykinin
Receptors: Structure and Activity Relationships. Current medicinal
chemistry. 11; 2004; 2045-81.
3. Björkqvist J, Sala-Cunill A, Renné T. Hereditary angioedema: a
bradykinin-mediated swelling disorder. Thromb Haemost. 2013;109: 368–74
4. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and
its interrelationships with complement. Mol Immunol. 2010;47: 2161–9
5. Hall JM. Bradykinin receptors. Gen Pharmacol. 1997(1):1-6.
6. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin
receptor subtype 1 expression and function in prostate cancer. Cancer
Res. 2003 ;63(9):2037-41.
7. Duka A, Duka I, Gao G, Shenouda S, Gavras I, Gavras H. Role of
bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J
Physiol Endocrinol Metab. 2006; 291: E268–74.
8. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner
JM, et al. Targeting kinin B (1) receptor for therapeutic
neovascularization. Circulation. 2002; 105:360–6
9. Lagneux C, Adam A, Lamontagne D. A study of the mediators involved in
the protection induced by exogenous kinins in the isolated rat heart.
Int Immunopharmacol. 2003;3: 1511–1518
10. Golias Ch, Charalabopoulos A, Stagikas D, Charalabopoulos K,
Batistatou A. The kinin system–bradykinin: biological effects and
clinical implications. Multiple role of the kinin system–bradykinin.
Hippokratia. 2007 Jul;11(3):124-8.
11. Terzuoli E, Corti F, Nannelli G, Giachetti A, Donnini S, Ziche M.
Bradykinin B2 Receptor Contributes to Inflammatory Responses in Human
Endothelial Cells by the Transactivation of the Fibroblast Growth Factor
Receptor FGFR-1. Int J Mol Sci. 2018 ;19(9):2638.
12. Duchêne J, Schanstra J, Cellier E, Bascands JL, Girolami JP [30
years: Happy birthday, GPCR. The bradykinin B2 receptor: an alternative
and antiproliferative pathway]. Nephrologie. 2002; 23(1):39-41.
13. Maggio JE. ”Tachykinins”. Annu. Rev. Neurosci. 1998; 11 :
13–28.
14. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. ”Diversity in
mammalian tachykinin peptidergic neurons: multiple peptides, receptors,
and regulatory mechanisms”. FASEB J . 1990; 4 (6):
1606–15.
15. Avanov AIa. ”Tachykinins and conformational aspects of their
interactions with receptors”. Mol. Biol. (Mosk) . 1992;26 (1): 5–24.
16. Boot JD, de Haas S, Tarasevych S, ”Effect of an NK1/NK2 receptor
antagonist on airway responses and inflammation to allergen in
asthma”. Am. J. Respir. Crit. Care Med .2007; 175 (5):
450–7.
17. Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C.
”Site-specific effects of intracerebral injections of three neurokinins
(neurokinin A, neurokinin K, and neurokinin gamma) on the expression of
male rat sexual behavior”. Physiol. Behav . 1993;54 (2):
249–58.
18. Grady EF, Gamp PD, Jones E, Baluk P, McDonald DM, Payan DG, Bunnett.
Endocytosis and recycling of neurokinin 1 receptors in enteric neurons.
NW Neuroscience. 1996; 75(4):1239-54.
19. Southwell BR, Seybold VS, Woodman HL, Jenkinson KM, Furness.
Quantitation of neurokinin 1 receptor internalization and recycling in
guinea-pig myenteric neurons. JB Neuroscience. 1998; 87(4):925-31.
20. Tachykinins and their functions in the gastrointestinal tract.
Shimizu Y, Matsuyama H, Shiina T, Takewaki T, Furness JB Cell Mol Life
Sci. 2008; 65(2):295-311.
21 . Deiteren A, De Winter BY, Nullens S, Pelckmans PA, De Man JG.
Role of tachykinin receptors in the modulation of colonic peristaltic
activity in mice. Eur J Pharmacol. 2011; 667(1-3):339-47.
22 . Hernandez J, Lackner A, Aye P, Mukherjee K, Tweardy DJ,
Mastrangelo MA, Weinstock J, Griffiths J, D’Souza M, Dixit S, Robinson
P. Substance P is responsible for physiological alterations such as
increased chloride ion secretion and glucose malabsorption in
cryptosporidiosis. Infect Immun. 2007; 75(3):1137-43.
23. The role of substance P, hemokinin and their receptor in governing
mucosal inflammation and granulomatous responses. Weinstock JV Front
Biosci. 2004; 9():1936-43.
24. Jerde TJ, Saban R, Bjorling DE, Nakada SY. NK-2 is the predominant
tachykinin receptor subtype in the swine ureter. BJU Int. 1999;
83(3):312-8.
25. Pinto FM, Ravina CG, Subiran N, Cejudo-Román A, Fernández-Sánchez M,
Irazusta J et al. Autocrine regulation of human sperm motility by
tachykinins. Reprod Biol Endocrinol. 2010; 8:104.
26. Song IS, Bunnett NW, Olerud JE, Harten B, Steinhoff M, Brown JR et
al. Substance P induction of murine keratinocyte PAM 212 interleukin 1
production is mediated by the neurokinin 2 receptor (NK-2R). Exp
Dermatol. 2000; 9(1):42-52.
27. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP,
Glorioso N et al. Cardiovascular phenotype of a mouse strain with
disruption of the bradykinin B2-receptor
gene. Circulation . 1997; 96:3570–8.
28. DomBourian, M. G. Turner, N. A. Gerovac, T. A. Vemuganti, R.
Miranpuri, G. S. Türeyen et al. B1 and TRPV-1 receptor genes and their
relationship to hyperalgesia following spinal cord injury. Spine. Phila.
Pa. 1976. 2006; 31: 2778–282;
29. Tang Z, Wang Z, Hu Z, Zhang M, Li L, Li B. The role of bradykinin in
lung ischemia-reperfusion injury in a rat lung transplantation model.
Acta Cir Bras. 2016;(12):807-812.
30. Bas, M., V. Adams, T. Suvorava, T. Niehues, T. K. Hoffmann, and G.
Kojda. “Nonallergic Angioedema: Role of Bradykinin.” Allergy 62, 2007;
(8): 842–56.
31. Roper M, Ham RG, Stewart JM. Biosynthesis of substance P in cultured
mouse neuroblastoma and rat glioma cells. Harkins J, Brain Res. 1978;
147(2):405-9.
32. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA,
Sampson JH, Kwatra MM. A constitutively active form of neurokinin 1
receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.J Neurochem. 2009 (4):1079-86.
33. Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M. The
NK-1 receptor is expressed in human primary gastric and colon
adenocarcinomas and is involved in the antitumor action of L-733,060 and
the mitogenic action of substance P on human gastrointestinal cancer
cell lines. Tumour Biol. 2008; (4):245-54.
34. Kradin R, MacLean J, Duckett S, Schneeberger EE, Waeber C, Pulmonary
response to inhaled antigen: neuroimmune interactions promote the
recruitment of dendritic cells to the lung and the cellular immune
response to inhaled antigen. Pinto C Am J Pathol. 1997(5):1735-43.
35. Augustyniak D, Jankowski A, Mackiewicz P, Skowyra A, Gutowicz J,
Drulis-Kawa Z. Innate immune properties of selected human neuropeptides
against Moraxella catarrhalis and non-typeable Haemophilus influenzae.
BMC Immunol. 2012; (13):24.
36. Okaya T, Holthaus R, Kato A, Lentsch AB, Involvement of the
neuropeptide substance P in lung inflammation induced by hepatic
ischemia/reperfusion. Inflamm Res. 2004;(6):257-61.
37. Rogers DF. Motor control of airway goblet cells and glands. Respir
Physiol. 2001 Mar; 125(1-2):129-44.
38. Horn CC, Wallisch WJ, Homanics GE, Williams JP.
Pathophysiological and neurochemical mechanisms of postoperative nausea
and vomiting. Eur J Pharmacol. 2014; (722): 55-66.
39. Kakoki M, Smithies O. The kallikrein kinin system in health and in
diseases of the kidney. Kidney Int. 2009, (75), 1019–30.
40. Merrifield, R.B. Solid-Phase Peptide Synthesis. III. An Improved
Synthesis of Bradykinin. Biochemistry 1964; (3), 1385–90.
41. Marceau, F; Bawolak, M.T.; Fortin, J.P.; Morissette, G.; Roy, C.;
Bachelard, H et al. Bifunctional ligands of the bradykinin B 2 and B 1
receptors: An exercise in peptide hormone plasticity. Peptides 2018,
(105), 37–50.
42. Cicardi, M.; Banerji, A.; Bracho, F.; Malbrán, A.; Rosenkranz, B.;
Riedl, M et al. Icatibant, a New Bradykinin-Receptor Antagonist, in
Hereditary Angioedema. N. Engl. J. Med. 2010, (363), 532–41.
43. Shakur, H.; Andrews, P.; Asser, T.; Balica, L.; Boeriu, C.;
Quintero, J.D.C et al. The BRAIN TRIAL: A randomised, placebo-controlled
trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients
with traumatic brain injury. Trials 2009, (10), 1–10.
44. Tenti, S.; Pascarelli, N.A.; Cheleschi, S.; Guidelli, G.M.;
Fioravanti, A. The Emerging Role of Bradykinin in the Pathogenesis of
Osteoarthritis and its Possible Clinical Implications. Curr. Rheumatol.
Rev. 2016, (12), 177–84
45. Balaguer, J.M.; Yu, C.; Byrne, J.G.; Ball, S.K.; Petracek, M.R.;
Brown, N.J et al. Contribution of endogenous bradykinin to fibrinolysis,
inflammation, and blood product transfusion following cardiac surgery: A
randomized clinical trial. Clin. Pharmacol. Ther. 2013, (93), 326–34.
46. Straka, B.T.; Ramirez, C.E.; Byrd, J.B.; Stone, E.; Woodard-Grice,
A.; Nian, H. et al. Effect of bradykinin receptor antagonism on ACE
inhibitor-associated angioedema. J. Allergy Clin. Immunol. 2017, (140),
242–8.
47. Pedersen, C.M.; Schmidt, M.R.; Barnes, G.; Bøtker, H.E.; Kharbanda,
R.K.; Newby, D.E et al. Bradykinin does not mediate remote ischaemic
preconditioning or ischaemia-reperfusion injury in vivo in man. Heart
2011, (97), 1857–61.
48. Whalley, E.T.; Figueroa, C.D.; Gera, L.; Bhoola, K.D. Discovery and
therapeutic potential of kinin receptor antagonists. Expert Opin. Drug
Discov. 2012, (7), 1129–48.
49. Warren, K.; Jakacki, R.; Widemann, B.; Aikin, A.; Libucha, M.;
Packer, R et al. Phase II trial of intravenous lobradimil and
carboplatin in childhood brain tumors: A report from the Children’s
Oncology Group. Cancer Chemother. Pharmacol. 2006, (58), 343–7.
50. Da Costa, P.L.N.; Sirois, P.; Tannock, I.F.; Chammas, R. The role of
kinin receptors in cancer and therapeutic opportunities. Cancer Lett.
2014, (345), 27–38.
51. Pruneau, D.; Bélichard, P.; Sahel, J.A.; Combal, J.P. Targeting the
kallikrein-kinin system as a new therapeutic approach to diabetic
retinopathy. Curr. Opin. Investig. Drugs 2010, (11), 507–14.
52. Bozó, É.; Éles, J.; Keser, G.M. Bradykinin B1 receptor antagonists:
A patent update 2009–2012. Expert Opin. Ther. Pat. 2012, (22),
1443–52.
53. Quartara L.; Altamura, M.
(August 2006), ”Tachykinin receptors antagonists: From research to
clinic”, Current Drug Targets, 7 (8): 975–992,
54. Lohr L (2008).
”Chemotherapy-induced nausea and vomiting”. Cancer Journal. 14 (2):
85–93.
55.
”FDA
approves Akynzeo for nausea and vomiting associated with cancer
chemotherapy”. Food
and Drug Administration. October 10, 2014. Archived
from the
original on February 1, 2017 . Retrieved march 17,2022.
56. Duffy RA, Morgan C, Naylor R,
Higgins GA, Varty GB, Lachowicz JE et al. ”Rolapitant (SCH 619734): a
potent, selective and orally active neurokinin NK1 receptor antagonist
with centrally-mediated antiemetic effects in ferrets”. Pharmacology,
Biochemistry, and Behavior. 2012; 102 (1): 95–100.
57. M. S. Kramer,N.Cutler, J. Feighner et al., “Distinctmechanism for
antidepressant activity by blockade of central substance P receptors,”Science , 1998; 281, (5383),1640–5.
58. M. Mu˜noz, M. Berger, M. Rosso, A. Gonzalez-Ortega, A. Carranza, and
R. Cove˜nas, “Antitumor activity of neurokinin-1 receptor antagonists
in MG-63 human osteosarcoma xenografts,” International Journal of
Oncology , 2014; 44, (1),137–46.
59. M. Munoz, A. Gonzalez-Ortega, M. V. Salinas-Martin et al., “The
neurokinin-1 receptor antagonist aprepitant is a promising candidate for
the treatment of breast cancer,” International Journal of
Oncology , 2014; 45,1658–72.
60. M. Berger, O. Neth, M. Ilmer et al., “Hepatoblastoma cells express
truncated neurokinin-1 receptor and can be growth inhibited by
aprepitant in vitro and in vivo,” Journal of Hepatology , 2014
60, (5),985–94.
61. M. Mu˜noz and M. Rosso, “The NK-1 receptor antagonist aprepitant as
a broad-spectrum antitumor drug,” Investigational NewDrugs , 2010, 28, (2), pp. 187–93.
62. Onori L, Aggio A, Taddei G, Tonini M: Contribution of NK (2)
tachykinin receptors to propulsion in the rabbit distal colon. Am J
Physiol 2000; (278): G137–47.
63. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L: Intestinal
anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats:
evidence to support a peripheral mechanism of action. Neurogastroenterol
Motil 2003; 15: 363–9.
64. Shafton AD, Bogeski G, Kitchener PD, Lewis VA, Sanger GJ, Furness
JB: Effects of the peripherally acting NK receptor antagonist,
SB-235375, on intestinal and somatic nociceptive responses and on
intestinal motility in anaesthetized rats. Neurogastroenterol Motil
2004; 16: 223–31.
65. Hwang L, Leichter R, Okamoto A, Payan D, Collins SM, Bunnett NW:
Downregulation of
neutral endopeptidase (EC 3.4.24.11) in the inflamed rat intestine. Am J
Physiol 1993; 264: G735–43.
66. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, Gerard N et al:
Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading
substance P. Proc Natl Acad Sci USA 1999; 96:11653–8.
67. Barbara G, De Giorgio R, Stanghellini V, Corinaldesi R, Cremon C,
Gerard N et al: Neutral endopeptidase (EC 3.4.24.11) downregulates the
onset of intestinal inflammation in the nematode infected mouse. Gut
2003; 52: 1457–64.
68. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et
al: GRADE guidelines: 3. Rating the quality of evidence. Journal of
Clinical Epidemiology. 2011, 64 (4): 401-6.
69. Joos GF, Pauwels RA: Tachykinin receptor antagonists: potential in
airways diseases. Current Opinion in Pharmacology. 2001, 1 (3): 235-41.
70. Schuiling M, Zuidhof AB, Zaagsma J, Meurs H: Involvement of
tachykinin NK1 receptor in the development of allergen-induced airway
hyperreactivity and airway inflammation in conscious, unrestrained
guinea pigs. Am J Respir Crit Care Med. 1999, 159 (2): 423-30.
71. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H et al. A
randomized, placebo controlled, double masked phase IB study evaluating
the safety and antiviral activity of aprepitant, a neurokinin-1 receptor
antagonist in HIV-1 infected adults. PLoS One. 2011;6(9): e24180.
72. Roberts, Claire; Inamdar, Amir; Koch, Annelize; Kitchiner, Pauline;
Dewit, Odile; Merlo-Pich, Emilio et al. A Randomized, Controlled Study
Comparing the Effects of Vestipitant or Vestipitant and Paroxetine
Combination in Subjects with Tinnitus, Otology & Neurotology:
2011;32;(5) 721-7
73. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A,
Luckenbaugh DA,et al. A selective neurokinin-1 receptor antagonist in
chronic PTSD: a randomized, double-blind, placebo-controlled,
proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar;21(3):221-9.
74. Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA;
Iris-2 investigators. The neurokinin-2 receptor antagonist ibodutant
improves overall symptoms, abdominal pain and stool pattern in female
patients in a phase II study of diarrhoea-predominant IBS. Gut. 2017;
66(8):1403-13.
75. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D
et al. Development of the 2nd generation neurokinin-1 receptor
antagonist LY686017 for social anxiety disorder. Eur
Neuropsychopharmacol. 2010 Feb;20(2):80-7.
76.
”GlaxoSmithKline
withdraws its marketing authorisation application for
Zunrisa” (PDF) . London: EMEA. 13 October 2009. Archived
from the
original (PDF) on 15 October 2009. Retrieved 21
December 2009
80. Saffroy M, Torrens Y, Glowinski J, et al. Autoradiographic
distribution of tachykinin NK2 binding sites in the rat brain:
comparison with NK1 and NK3 binding sites. Neuroscience 2003; 116:761-73
81. Le Fur G. In: Sanofi-Synthe´labo Information Meeting, February 16,
2004, 53-6
82. Hopkins CR. ACS chemical neuroscience molecule spotlight on
Saredutant. ACS Chemical Neuroscience. 2010 Oct;1(10):653-4.
83. Rayes, N., Bowen, D.J., Coffin, T. et al. MAGENTA (Making
Genetic testing accessible): a prospective randomized controlled trial
comparing online genetic education and telephone genetic counseling for
hereditary cancer genetic testing. BMC Cancer 2019;
19, 648.
84. Almeida TA, Rojo J, Nieto PM, et al. Tachykinin and tachykinin
receptors: structure and activity relationships. Curr Med Chem 2004;
11:2045-81
85. Rigby M, O’Donnell R, Rupniak NM. Species differences in tachykinin
receptor
distribution: further evidence that the substance P (NK1) receptor
predominates
in human brain. J Comp Neurol 2005; 490:335-53
86. Couture R, Toma N, Barbot L. SR142801 behaves as a tachykinin NK-3
receptor
agonist on a spinal nociceptive reflex in the rat. Life Sci 2000;
66:51-65
87. Meltzer HY, Arvanitis L, Bauer D, et al. A placebo-controlled
evaluation of four novel compounds for the treatment of schizophrenia
and schizoaffective disorders. Am J Psychiat 2004; 161:975-84
88. GSK R&D Day 2003. Psychiatry update
89. Gorelik, G., Carbini, L. A. & Scicli, A. G. Angiotensin 1–7
induces bradykinin- mediated relaxation in porcine coronary artery.J. Pharmacol. Exp. Ther. 1998; 286,403–10.
90. Bossi, F. et al. Platelet- activating factor and kinindependent
vascular leakage as a novel functional activity of the soluble terminal
complement complex. J. Immunol. 2004; 173, 6921–7.
91. Turner DJ, Guota K, Yang XX, Martin JG. Bradykinin-induced airway
constriction in guinea-pigs: role of leukotriene D4. Pulm Pharmacol Ther
2000; 13:181–188.
92. Arakawa, M., Majima, M., Nagai, K. et al. Role of tachykinins
in enhancement of bradykinin-induced bronchoconstriction by
captopril. Inflamm Res 1996; 45, 75–82.